Xcell Amnio Matrix

PreclinicalBiologic

NNew Horizon Medical Solutions

Xcell Amnio Matrix is one of 37 biologic programs targeting Effectiveness. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EffectivenessRecruiting

EffectivenessPreclinical

Recruiting

Competition

Competitive Landscape

76 competitors in Effectiveness

#DrugCompanyPhaseTrials

Kesimpta

Novartis

Phase 3

2 2

Mounjaro

Eli Lilly

Phase 3

1 3

Actos

Takeda

Phase 3

1 4

Elucirem

GGuerbet

Phase 3

1 5

Nicotine Free Cigarettes

Pfizer

Phase 3

3 6

Lidocain

Bayer

Phase 3

1 7

Botulinum Toxin a

GSK

Phase 3

1 8

Pneumococcal Conjugate Vaccine

Novartis

Phase 3

1 9

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 10

DTG/3TC

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness1 trial

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

Recruiting·NNew Horizon Medical Solutions·N/A·NCT07116174·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Xcell Amnio Matrix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xcell Amnio Matrix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xcell Amnio Matrix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New Horizon Medical Solutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: NNew Horizon Medical Solutions

Xcell Amnio Matrix

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News